Concepedia

Author

Elizabeth Tan-Chiu

NSABP Foundation

Also Known As

E Tan-Chiu, E. Tan-Chiu, E. Tanchiu, Elizabeth Tan-Chiu, Elizabeth Tan-chiu

76

Publications

18.4K

Citations

27

H-Index

39

Concepts

All Affiliations

NSABP FoundationUniversity of PittsburghFlorida Cancer CareAllegheny General HospitalResearch Network (United States)
ET

About

Elizabeth Tan-Chiu is an author at NSABP Foundation specializing in medicine, breast cancer, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

8

8

906

2

Health Sciences

2

2

632

3

Cell Biology

2

2

32

4

Natural Sciences

1

1

22

5

Biochemistry

1

1

22

Elizabeth Tan-Chiu

×

29

Publications

18.1K

Citations

25

H-Index

YearCitations

Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

Bernard Fisher, Joseph P. Costantino, D. Lawrence Wickerham,

JNCI Journal of the National Cancer Institute

1998

5.5K

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

Edward H. Romond, Edith A. Perez, John Bryant,

New England Journal of Medicine

2005

5.3K

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31

Elizabeth Tan-Chiu, Greg Yothers, Edward H. Romond,

Journal of Clinical Oncology

2005

801

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

Howard A. Burris, Hope S. Rugo, Svetislava J. Vukelja,

Journal of Clinical Oncology

2010

758

erbB-2 and Response to Doxorubicin in Patients With Axillary Lymph Node-Positive, Hormone Receptor- Negative Breast Cancer

Soonmyung Paik, John Bryant, Chanheun Park,

JNCI Journal of the National Cancer Institute

1998

653

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen,

The Lancet Oncology

2017

578

Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Edward H. Romond, Jong‐Hyeon Jeong, Priya Rastogi,

Journal of Clinical Oncology

2012

514

Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17

Edwin R. Fisher, James J. Dignam, Elizabeth Tan-Chiu,

Cancer

1999

501

Real-World Performance of HER2 Testing--National Surgical Adjuvant Breast and Bowel Project Experience

Soonmyung Paik, Jennifer Bryant, Elizabeth Tan-Chiu,

JNCI Journal of the National Cancer Institute

2002

496

Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Five National Surgical Adjuvant Breast and Bowel Project Node-Positive Adjuvant Breast Cancer Trials

Irene Wapnir, Stewart Anderson, Eleftherios P. Mamounas,

Journal of Clinical Oncology

2006

457

Page 1